

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR
(2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR
AND
(3) CHANGE IN THE COMPOSITION OF BOARD COMMITTEE

The Board hereby announces the resignation of non-executive Director, proposed appointment of non-executive Director and change in the composition of Board committee as follows:

- (1) Mr. Yao Fang resigned as a non-executive Director due to work reassignment, and ceased to be a member of the Strategic Committee of the Board, both with effect from 30 June 2024;
- (2) proposed to appoint Mr. Chen Yuqing (陳玉卿) as non-executive Director of the ninth session of the Board; and
- (3) Mr. Wang Kexin has been appointed as a member of the Strategic Committee of the Board, with effect from 1 July 2024.

CIRCULAR

A circular containing, among others, further details regarding the proposed appointment of Mr. Chen Yuqing as a non-executive Director and a notice of the general meeting will be dispatched to the Shareholders in due course.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

On 30 June 2024, the board (“**Board**”) of directors (“**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) received a resignation letter from Mr. Yao Fang (“**Mr. Yao**”). Mr. Yao resigned as a non-executive Director due to work reassignment, and ceased to be a member of the strategic committee of the Board (“**Strategic Committee**”). In accordance with the articles of association of the Company, the resignation of Mr. Yao shall become effective from 30 June 2024.

Mr. Yao has confirmed that there is no disagreement between him and the Board and/or the Company during his term of office and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

The Company hereby expresses its sincere gratitude to Mr. Yao for his valuable contribution during his term of office.

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce the proposed appointment of Mr. Chen Yuqing (“**Mr. Chen**”) as a non-executive Director of the ninth session of the Board. The appointment of Mr. Chen is subject to the approval of the Shareholders at the general meeting. The biographical details of Mr. Chen are set out as follows:

Mr. Chen Yuqing, aged 48. Prior to joining the Group, Mr. Chen Yuqing had been a teacher at the School of Materials of Shanghai University, the human resources manager of each of Yanfeng Visteon Automotive Trim Systems Co., Ltd.* (延鋒偉世通汽車飾件系統有限公司) (now renamed as Yanfeng Automotive Trim Systems Co., Ltd.* (延鋒汽車飾件系統有限公司)), Yanfeng Visteon (Beijing) Automotive Trim Systems Co., Ltd.* (延鋒偉世通(北京)汽車飾件系統有限公司) and Shanghai Yanfeng Johnson Controls Seating Co., Ltd.* (上海延鋒江森座椅有限公司), the development manager of the human resources department of Shanghai Alison (Group) Co., Ltd.* (上海埃力生(集團)有限公司), the Central China human resources manager of Schindler China Elevator Co. Ltd.* (迅達(中國)電梯有限公司), the senior human resources integration manager of Global Mart Limited* (購寶商業集團), and the chief human resources officer of Kubao Information Technology (Shanghai) Co., Ltd.* (酷寶信息技術(上海)有限公司) from July 1997 to October 2009. Mr. Chen Yuqing served in various positions including the deputy supervisor of human resources department, deputy general manager of human resources department, general manager of human resources department, the assistant to the president and general manager of the human resources department of the Company from January 2010 to April 2015; the vice president of the Company from April 2015 to June 2016; senior vice president of the Company from June 2016 to October 2020; the co-president of the Company from October 2020 to June 2022; a co-chief executive officer of the Company from June 2022 to June 2023; chairman of Shanghai Fosun Health Technology (Group) Co., Ltd.* (上海復星健康科技(集團)有限公司) (“**Fosun Health**”), a subsidiary of the Company, from August 2020 to May 2021 and from October 2022 to present, and holds directorships in certain subsidiaries of Fosun Health; and vice president of the Fosun International Limited (stock code: 00656), a company listed on The Stock Exchange of Hong Kong Limited, from July 2023 to present. Mr. Chen Yuqing obtained a bachelor degree in engineering from Shanghai University.

As at the date of this announcement, Mr. Chen has not entered into a service contract as a Director with the Company. Mr. Chen will not receive any remuneration from the Company for his appointment as a non-executive Director, and the relevant directors’ service contract will not provide for a specific remuneration amount. The proposed appointment of Mr. Chen as a non-executive Director of ninth session of the Board will be effective upon the approval of the Shareholders at the general meeting and end on the expiration of the term of ninth session of the Board.

Mr. Chen has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any directors (the “**Directors**”), other supervisors, senior management or substantial or controlling shareholders of the Company, and does not hold any other positions in the Company or any its subsidiaries nor any other directorships in listed public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years. Mr. Chen has personal interests in 134,000 A shares and 20,000 H shares of the Company as at the date of this announcement, representing approximately 0.0063% of the Company’s total number of issued A Shares, approximately 0.0036% of the Company’s total number of issued H shares and in aggregate approximately 0.0058% of the total number of issued shares of the Company, respectively. Save as disclosed above, Mr. Chen does not have any interests or short position in any shares or underlying shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. There are no other matters concerning Mr. Chen that need to be brought to the attention of the Shareholders.

CHANGE IN THE COMPOSITION OF STRATEGIC COMMITTEE OF THE BOARD

Given Mr. Yao resigned as a non-executive Director and ceased to be a member of the Strategic Committee with effective from 30 June 2024, the Board announces that Mr. Wang Kexin has been appointed as a member of the Strategic Committee with effect from 1 July 2024.

CIRCULAR

A circular, containing, among others, further details regarding the proposed appointment of Mr. Chen as a non-executive Directors and a notice of the general meeting will be dispatched to the Shareholders in due course.

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
1 July 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* For identification purposes only